Sotorasib in KRAS G12C-mutated NSCLC: A multicenter real-world experience from the expanded access program in Germany

被引：2
|
作者：
Althoff, F. C. [1 ]
Stratmann, J. A. [1 ]
Doebel, P. [1 ]
Hunerlituerkoglu, A. N. [2 ]
Frost, N. [3 ,4 ]
Christopoulos, P. [5 ]
Zum Bueschenfelde, C. Meyer [6 ]
Alt, J. [7 ]
Webendoerfer, M. [8 ]
Kaldune, S. [9 ]
Tritchkova, G. [10 ]
Waller, C. F. [11 ]
Braess, J. [12 ]
Kopp, H-G. [13 ]
Grohe, C. [14 ]
Schumann, C. [15 ]
Griesinger, F. [16 ]
Kuon, J. B. [17 ]
Sebastian, M.
Reinmuth, N. [18 ]
机构：
[1] Johannes Wolfgang Goethe Univ, Haematol Oncol, Univ Klinikum Frankfurt, Frankfurt, Germany
[2] Helios Klinikum Krefeld, Hematol Oncol, Krefeld, Germany
[3] Univ Klin, Dept Infect Dis & Pneumonol, Berlin, Germany
[4] Charite Campus Virchow Klinikum, Berlin, Germany
[5] Thoraxklin Heidelberg gGmbH, Dept Oncol Thorac Tumors, Heidelberg, Germany
[6] ViDia Karlsruhe Diakonissenkrankenhaus, Hematol Oncol, Karlsruhe, Germany
[7] Univ Med Mainz, Med Klin Poliklin 3, Mainz, Germany
[8] Univ Klinikum Essen, Med Oncol, Essen, Germany
[9] RoMed Klinikum Rosenheim, Med Klin, Rosenheim, Germany
[10] Tech Univ Dresden, Internal Med, Carl Gustav Carus Fac Med, Dresden, Germany
[11] Univ Klinikum Freiburg, Hematol Oncol & Stem Cell Transplantat, Klin Innere Med Hamatol Onkol & Stammzelltranspla, Freiburg, Germany
[12] St John Gods Hosp, Hematol Med Oncol, Regensburg, Germany
[13] Robert Bosch Kran Kenhaus, Dept Hematol Oncol, Stuttgart, Germany
[14] ELK Berlin Chest Hosp, Pneumol, Evangel Lungenklin, Berlin, Germany
[15] Klinikum Kempten Oberallgaeu gGmbH, Klin Pneumol Thoraxonkol Schlaf & Beamtungsmed, Kempten, Germany
[16] Pius Hosp, Dept Oncol, Oldenburg, Germany
[17] SLK Kliniken Heilbronn GmbH, Thorac Oncol Dept, Heilbronn, Germany
[18] Asklepios Fachklinikum, Thorac Oncol, Gauting, Germany
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.2437
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1405P
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Long-Term Outcomes with Sotorasib in KRAS G12cMutated Advanced NSCLC from the Global Expanded Access Program (EAP) Study-436
    Novello, S.
    Maimon, N.
    Stevenson, J.
    Petty, W.
    Ferreira, C. G.
    Morbeck, I.
    Zer, A.
    Bauman, J.
    Kalmadi, S.
    Xia, C.
    Meloni, A. R.
    Mehta, B.
    Ardito-Abraham, C.
    Kormany, W.
    Awad, M.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S352 - S353
  • [32] Biomarkers of acquired resistance to sotorasib (soto) plus panitumumab (pani) in chemorefractory KRAS G12C-mutated metastatic colorectal cancer (mCRC)
    Hong, David S.
    Kuboki, Yasutoshi
    Yaeger, Rona
    Strickler, John H.
    Masuishi, Toshiki
    Langer, Corey
    Shergill, Ardaman
    Kim, Edward
    Hindoyan, Antreas
    Tran, Qui
    Mukundan, Lata
    Chan, Emily
    Anderson, Abraham
    Fakih, Marwan G.
    CANCER RESEARCH, 2023, 83 (07)
  • [33] Sotorasib in combination with panitumumab in refractory KRAS G12C-mutated colorectal cancer: Safety and efficacy for phase Ib full expansion cohort
    Kuboki, Y.
    Yaeger, R.
    Fakih, M.
    Strickler, J. H.
    Masuishi, T.
    Kim, E. J-H.
    Bestvina, C. M.
    Langer, C. J.
    Krauss, J. C.
    Puri, S.
    Cardona, P.
    Chang, E. K.
    Tran, Q.
    Hong, D. S.
    ANNALS OF ONCOLOGY, 2022, 33 : S1445 - S1446
  • [34] Sotorasib in combination with panitumumab in refractory KRAS G12C-mutated colorectal cancer: Safety and efficacy for phase Ib full expansion cohort
    Kuboki, Y.
    Yaeger, R.
    Fakih, M. G.
    Strickler, J. H.
    Masuishi, T.
    Kim, E. J.
    Bestvina, C. M.
    Langer, C. J.
    Krauss, J. C.
    Puri, S.
    Cardona, P.
    Chan, E.
    Tran, Q.
    Hong, D. S.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S680 - S681
  • [35] Efficacy of Sotorasib Versus Standard Chemotherapy plus Immunotherapy in KRAS G12C Mutated Lung Cancer: A Comparative Study Modeling Real-World Data
    Haddad, P.
    Hammoud, D.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (03) : E28 - E28
  • [36] Efficacy and safety outcomes in patients receiving sotorasib for advanced KRAS G12C-mutated non-small cell lung cancer
    Milner-Watts, Charlotte
    O'Sullivan, Hazel
    Stewart, James
    Idaikkadar, Praveena
    Tokaca, Nadza
    Davidson, Michael
    Yousaf, Nadia
    Bhosle, Jaishree
    Popat, Sanjay
    O'Brien, Mary
    Minchom, Anna
    LUNG CANCER, 2023, 178 : S31 - S32
  • [37] Real-world clinicopathological and molecular characteristics, treatment patterns, and outcomes in patients with KRAS G12C-mutated metastatic colorectal cancer in AACR Project GENIE.
    Hsu, Hil
    Aggarwal, Shivani
    Balan, Archana
    Ricciuti, Biagio
    Egger, Jacklynn V.
    LeNoue-Newton, Michele
    Holt, Marilyn Elaine
    Lee, Jocelyn
    Chia, Victoria M.
    Chan, Emily
    Rehn, Marko
    Wang, Xuena
    Lovly, Christine M.
    Riely, Gregory J.
    Awad, Mark M.
    Anagnostou, Valsamo
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 41 - 41
  • [38] Genomic Profiles and Potential Determinants of Response and Resistance in KRAS p.G12C-mutated NSCLC Treated With Sotorasib
    Skoulidis, F.
    Schuler, M.
    Wolf, J.
    Barlesi, F.
    Price, T.
    Dy, G.
    Govindan, R.
    Borghaei, H.
    Falchook, G.
    Li, B.
    Ramalingam, S.
    Sacher, A.
    Spira, A.
    Takahashi, T.
    Anderson, A.
    Ang, A.
    Dai, T.
    Flesher, D.
    Cifuentes, P.
    Velcheti, V.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S929 - S930
  • [39] Rapid Response to Sotorasib of a Patient With KRAS G12C-Mutated Lung Cancer With Cancer-Associated Disseminated Intravascular Coagulation: A Case Report
    Kunimasa, Kei
    Tamiya, Motohiro
    Inoue, Takako
    Kawamura, Takahisa
    Nishino, Kazumi
    JTO CLINICAL AND RESEARCH REPORTS, 2023, 4 (01):
  • [40] Real-world outcomes in patients with KRAS G12C-mutated advanced non-small cell lung cancer treated with docetaxel in second-line or beyond
    Gray, Jhanelle E.
    Hsu, Hil
    Younan, Diana
    Suri, Gaurav
    Chia, Victoria
    Spira, Alexander
    Johnson, Melissa
    LUNG CANCER, 2023, 181
12345